feedback

Faculty

Ian W. Flinn, MD, PhD
Director of Lymphoma/CLL Program
Sarah Cannon Center for Blood Cancer
Nashville, TN


Richard R. Furman, MD
The Morton Coleman, MD Distinguished Associate Professor of Medicine
Division of Hematology and Oncology
Weill Cornell Medical College
New York, NY


William G. Wierda, MD, PhD
Distinguished Professor, D.B. Lane Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, TX


Activity Details

Free
CME

1.0 AMA PRA Category 1 Credit

Released: April 11, 2017

Expires: April 11, 2018

1 hour to complete

Registration required

Target Audience

Oncology specialists, including physicians, nurse practitioners, and PAs

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Implement advances in chronic lymphocytic leukemia (CLL) testing to help refine diagnosis, predict prognosis, and select the most appropriate personalized treatment approaches
  2. Utilize new and emerging targeted treatments for CLL patients based on efficacy, clinical trial data, and guidelines in order to individualize treatment regimens
  3. Integrate evidence-based strategies into the management of side effects associated with CLL treatments

Activity Description

This curriculum is designed to assist clinicians in developing patient-personalized treatment plans by using evidence-based diagnostic and therapeutic approaches for newly diagnosed, relapsed, and elderly CLL patients. Clinicians will learn from a series of challenging CLL patient cases and reflect on errors and missed opportunities in diagnosis, treatment, and recognition of treatment-related adverse events.

Financial Disclosure

The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relevant relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. Albert Einstein College of Medicine, CCME staff, has no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests, but these relationships will not affect their ability to have an unbiased contribution to the educational content of this CME activity:

  • Ian W. Flinn, MD, PhD, has affiliations with Acerta, BeiGene, Celgene, Genentech, Gilead, Infinity, Janssen, and TG Therapeutics (Contracted Research).
  • Richard R. Furman, MD, has affiliations with AbbVie, Genentech, Gilead, Janssen, and Pharmacyclics (Consulting Fees); and Pharmacyclics (Speakers Bureau).
  • William G. Wierda, MD, PhD, has affiliations with AbbVie, Celgene, Emergent, Genentech/Roche, Genzyme, Gilead, GlaxoSmithKline/Novartis, Merck, Pharmacyclics, and Sanofi (Consulting Fees); AbbVie, Ascerta, Emergent, Genentech, Gilead, GlaxoSmithKline/Novartis, Janssen, Juno, Karyopharm, Kite Pharma, and Pharmacyclics (Contracted Research).

RMEI Medical Education, LLC

  • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
  • Chelsey Goins, PhD, has no affiliations with commercial interests to disclose.
  • Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
  • Leslie Treff, JD, has no affiliations with commercial interests to disclose.

The following Einstein peer reviewer reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Amit K. Verma, MBBS, has no affiliations with commercial interests to disclose.

Accreditation Statement


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and RMEI Medical Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Albert Einstein College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and physician assistants are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

Commercial Support

This activity is supported by an independent educational grant from AbbVie.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Albert Einstein College of Medicine, Montefiore Medical Center, RMEI Medical Education, LLC, or AbbVie. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.